Avantax Advisory Services, Inc. Crispr Therapeutics Ag Transaction History

Avantax Advisory Services, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$51.17 - $68.18 $23,691 - $31,567	-463 Reduced 9.67%	4,324 $233,000
Q1 2024 May 08, 2024	SELL	$60.67 - $89.12 $40,102 - $58,908	-661 Reduced 12.13%	4,787 $326,000
Q4 2023 Feb 07, 2024	BUY	$38.62 - $72.18 $210,401 - $393,236	5,448 New	5,448 $341,000
Q4 2022 Feb 13, 2023	BUY	$39.19 - $65.67 $37,308 - $62,517	952 Added 14.53%	7,503 $304,000
Q3 2022 Nov 01, 2022	BUY	$61.1 - $83.78 $7,148 - $9,802	117 Added 1.82%	6,551 $428,000
Q2 2022 Aug 02, 2022	BUY	$43.23 - $73.83 $45,694 - $78,038	1,057 Added 19.66%	6,434 $391,000
Q1 2022 Apr 27, 2022	BUY	$53.19 - $79.24 $41,435 - $61,727	779 Added 16.94%	5,377 $344,000
Q4 2021 Jan 24, 2022	BUY	$70.09 - $111.29 $12,476 - $19,809	178 Added 4.03%	4,598 $348,000
Q3 2021 Oct 21, 2021	BUY	$110.2 - $156.64 $65,789 - $93,514	597 Added 15.62%	4,420 $494,000
Q2 2021 Jul 29, 2021	BUY	$100.84 - $161.89 $169,814 - $272,622	1,684 Added 78.73%	3,823 $620,000
Q1 2021 May 13, 2021	BUY	$110.72 - $210.04 $236,830 - $449,275	2,139 New	2,139 $260,000

489

57.9M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.1B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

Stay updated on Avantax Advisory Services, Inc. with notifications on news.